相似文献
1
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters.
BioDrugs. 2015 Aug;29(4):215-39. doi: 10.1007/s40259-015-0133-6.
2
Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain.
MAbs. 2012 Nov-Dec;4(6):673-85. doi: 10.4161/mabs.22242.
3
N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance.
Eur J Pharm Biopharm. 2019 Jun;139:123-131. doi: 10.1016/j.ejpb.2019.03.018. Epub 2019 Mar 21.
4
Half-life extension using serum albumin-binding DARPin® domains.
Protein Eng Des Sel. 2017 Sep 1;30(9):583-591. doi: 10.1093/protein/gzx022.
5
Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β.
Immunol Lett. 2019 Mar;207:46-55. doi: 10.1016/j.imlet.2019.01.009. Epub 2019 Jan 23.
6
Albumin-binding domain extends half-life of glucagon-like peptide-1.
Eur J Pharmacol. 2021 Jan 5;890:173650. doi: 10.1016/j.ejphar.2020.173650. Epub 2020 Oct 10.
7
Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action.
Bioorg Med Chem. 2018 Jun 1;26(10):2882-2887. doi: 10.1016/j.bmc.2017.09.016. Epub 2017 Sep 15.
8
Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study.
Drugs R D. 2011;11(1):61-75. doi: 10.2165/11588270-000000000-00000.
9
Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.
Curr Opin Biotechnol. 2009 Dec;20(6):692-9. doi: 10.1016/j.copbio.2009.10.010. Epub 2009 Nov 4.
10
Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins.
J Biotechnol. 2017 Jul 10;253:23-33. doi: 10.1016/j.jbiotec.2017.05.017. Epub 2017 May 24.
引用本文的文献
1
A long-lasting prolactin stimulates galactopoiesis in mice.
iScience. 2025 Jul 15;28(8):113112. doi: 10.1016/j.isci.2025.113112. eCollection 2025 Aug 15.
2
Exploring glycoform-dependent dynamic modulations in human immunoglobulin G via computational and experimental approaches.
Proc Natl Acad Sci U S A. 2025 Aug 12;122(32):e2505473122. doi: 10.1073/pnas.2505473122. Epub 2025 Aug 5.
3
Novel loop structure of human IgG1 Fc fused CD38 targeted bispecific antibodies and their anti-tumor effect in acute myeloid leukemia.
J Transl Med. 2025 Jul 28;23(1):849. doi: 10.1186/s12967-025-06827-2.
4
Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications.
Chem Rev. 2025 Aug 13;125(15):7099-7166. doi: 10.1021/acs.chemrev.4c00989. Epub 2025 Jul 23.
5
Engineered IL-18 variants with half-life extension and improved stability for cancer immunotherapy.
J Immunother Cancer. 2025 Jul 15;13(7):e011789. doi: 10.1136/jitc-2025-011789.
6
Identification of a direct interaction between the Fab domains of IgG antibodies and human FcRn upon IgG-FcRn complex formation.
Commun Biol. 2025 Jun 12;8(1):922. doi: 10.1038/s42003-025-08252-z.
7
Engineering of long-acting human growth hormone-Fc fusion proteins: Effects of valency, fusion position, and linker design on pharmacokinetics and efficacy.
PLoS One. 2025 May 15;20(5):e0323791. doi: 10.1371/journal.pone.0323791. eCollection 2025.
8
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury.
Proc Natl Acad Sci U S A. 2025 Apr 22;122(16):e2424754122. doi: 10.1073/pnas.2424754122. Epub 2025 Apr 14.
9
An ACE2-Fc decoy produced in glycoengineered plants neutralizes ancestral and newly emerging SARS-CoV-2 variants and demonstrates therapeutic efficacy in hamsters.
Sci Rep. 2025 Apr 2;15(1):11307. doi: 10.1038/s41598-025-95494-w.
10
Design of a novel long-acting insulin analogs by acetylation modification and compared with insulin Icodec.
Sci Rep. 2025 Mar 19;15(1):9408. doi: 10.1038/s41598-025-94014-0.
本文引用的文献
1
Chimeric fusion proteins used for therapy: indications, mechanisms, and safety.
Drug Saf. 2015 May;38(5):455-79. doi: 10.1007/s40264-015-0285-9.
2
Reductions in synaptic proteins and selective alteration of prepulse inhibition in male C57BL/6 mice after postnatal administration of a VIP receptor (VIPR2) agonist.
Psychopharmacology (Berl). 2015 Jun;232(12):2181-9. doi: 10.1007/s00213-014-3848-z. Epub 2015 Jan 11.
3
Fc fusion as a platform technology: potential for modulating immunogenicity.
Trends Biotechnol. 2015 Jan;33(1):27-34. doi: 10.1016/j.tibtech.2014.11.001. Epub 2014 Dec 6.
4
The effects of fusion structure on the expression and bioactivity of human brain natriuretic peptide (BNP) albumin fusion proteins.
Curr Pharm Biotechnol. 2014;15(9):856-63. doi: 10.2174/1389201015666141012182106.
5
Half-life extension technologies for haemostatic agents.
Thromb Haemost. 2015 Jan;113(1):165-76. doi: 10.1160/TH14-04-0332. Epub 2014 Oct 2.
6
GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety.
Clin Pharmacol Ther. 2014 Dec;96(6):704-12. doi: 10.1038/clpt.2014.187. Epub 2014 Sep 19.
7
Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis.
J Biol Chem. 2014 Oct 17;289(42):29014-29. doi: 10.1074/jbc.M114.602474. Epub 2014 Sep 5.
8
Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice.
PLoS One. 2014 Jul 24;9(7):e102566. doi: 10.1371/journal.pone.0102566. eCollection 2014.
9
Characterisation of a novel Fc conjugate of macrophage colony-stimulating factor.
Mol Ther. 2014 Sep;22(9):1580-92. doi: 10.1038/mt.2014.112. Epub 2014 Jun 25.
10
Co-opting biology to deliver drugs.
Biotechnol Bioeng. 2014 Sep;111(9):1699-716. doi: 10.1002/bit.25307. Epub 2014 Jul 21.
Zotero 插件